Aprea Therapeutics’ (APRE) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research report report published on Monday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright also issued estimates for Aprea Therapeutics’ Q4 2024 earnings at ($0.54) EPS, FY2024 earnings at ($2.39) EPS, FY2025 earnings at ($0.95) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.61) EPS.

Separately, Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a report on Tuesday, August 13th.

Aprea Therapeutics Stock Down 0.3 %

NASDAQ APRE opened at $3.01 on Monday. The stock has a market cap of $16.36 million, a P/E ratio of -1.07 and a beta of 0.97. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $8.85. The company’s 50-day simple moving average is $3.32 and its 200 day simple moving average is $3.85.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.11. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The business had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.45 million. Research analysts anticipate that Aprea Therapeutics will post -2.56 earnings per share for the current year.

Insider Activity at Aprea Therapeutics

In other news, Director Marc Duey bought 30,000 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were bought at an average cost of $4.39 per share, for a total transaction of $131,700.00. Following the completion of the acquisition, the director now owns 240,113 shares in the company, valued at approximately $1,054,096.07. This trade represents a 14.28 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bernd R. Seizinger bought 10,000 shares of the business’s stock in a transaction on Friday, October 11th. The stock was purchased at an average price of $2.68 per share, for a total transaction of $26,800.00. Following the completion of the acquisition, the director now owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. This trade represents a 28.79 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 42,290 shares of company stock worth $165,096 over the last ninety days. Company insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics makes up about 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st largest holding. Stonepine Capital Management LLC owned approximately 2.53% of Aprea Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.